81 related articles for article (PubMed ID: 21112630)
1. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
2. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(1):99-103. PubMed ID: 21282741
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
5. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
Schmidt M; Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(3):325-33. PubMed ID: 21576405
[TBL] [Abstract][Full Text] [Related]
6. Targeting Wnt pathway in lymphoma and myeloma cells.
Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
[No Abstract] [Full Text] [Related]
7. Griseofulvin Efficiently Induces Apoptosis in
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Schmidt-Wolf IGH
Anticancer Res; 2017 May; 37(5):2289-2295. PubMed ID: 28476794
[TBL] [Abstract][Full Text] [Related]
8. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
9. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
11. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
12. Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Mar; 35(3):1369-76. PubMed ID: 25750287
[TBL] [Abstract][Full Text] [Related]
13. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Blaum-Feder S; Schmidt-Wolf IG
Anticancer Res; 2015 Nov; 35(11):5921-6. PubMed ID: 26504016
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
[TBL] [Abstract][Full Text] [Related]
16. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
18. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
19. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]